New England Journal of Medicine 366: 1181-9 (March 29, 2012)
COPY LINK
New England Journal of Medicine 366: 1181–1189
Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis
Kim A. Papp, Craig Leonardi, Alan Menter, Jean-Paul Ortonne, James G. Krueger, Gregory Kricorian, Girish Aras, Juan Li, Chris B. Russell, Elizabeth H.Z. Thompson, and Scott Baumgartner
We assessed the efficacy and safety of brodalumab (AMG 827), a human anti-interleukin-17-receptor monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis. An improvement of at least 75% and at least 90% in the PASI score at week 12 was seen in 77% and 72%, respectively, of the patients in the 140-mg brodalumab group and in 82% and 75%, respectively, of the patients in the 210-mg group, as compared with 0% in the placebo group (P<0.001 for all comparisons). Brodalumab significantly improved plaque psoriasis in this 12-week, phase 2 study.
